Research Paper Volume 15, Issue 19 pp 10453—10472
An immune signature to predict the prognosis of ATRX-wildtype glioma patients and guide immune checkpoint blockade therapy
Figure 1. Stromal and immune scores were associated with survival in ATRX-wt glioma patients. (A) Flow chart of the analytical process in this study. (B) Kaplan-Meier survival analysis for ATRX-mt glioma patients in the high- and low-immune-score groups. (C) Kaplan-Meier survival analysis for ATRX-mt glioma patients in the high- and low-stromal-score groups. (D) Kaplan-Meier survival analysis for ATRX-wt glioma patients in the high- and low-immune-score groups. (E) Kaplan-Meier survival analysis for ATRX-wt glioma patients in the high- and low-stromal-score groups.